Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease

Xinrong Tao, Tania Garron, Anurodh Shankar Agrawal, Abdullah Algaissi, Bihung Peng, Maki Wakamiya, Teh Sheng Chan, Lu Lu, Lanying Du, Shibo Jiang, Robert B. Couch, Chien-Te Tseng

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Characterized animal models are needed for studying the pathogenesis of and evaluating medical countermeasures for persisting Middle East respiratory syndrome-coronavirus (MERS-CoV) infections. Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease that globally expresses human CD26 (hCD26)/DPP4. The 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively. Neutralizing antibody developed in the surviving mice from the ID50/LD50 determinations, and all were fully immune to challenge with 100 LD50 of MERS-CoV. The tissue distribution and histopathology in mice challenged with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated. In contrast to the overwhelming infection seen in the mice challenged with 105 LD50 of MERS-CoV, we were able to recover infectious virus from these mice only infrequently, although quantitative reverse transcription-PCR (qRT-PCR) tests indicated early and persistent lung infection and delayed occurrence of brain infection. Persistent inflammatory infiltrates were seen in the lungs and brain stems at day 2 and day 6 after infection, respectively. While focal infiltrates were also noted in the liver, definite pathology was not seen in other tissues. Finally, using a receptor binding domain protein vaccine and a MERS-CoV fusion inhibitor, we demonstrated the value of this model for evaluating vaccines and antivirals against MERS. As outcomes of MERS-CoV infection in patients differ greatly, ranging from asymptomatic to overwhelming disease and death, having available both an infection model and a lethal model makes this transgenic mouse model relevant for advancing MERS research.

Original languageEnglish (US)
Pages (from-to)57-67
Number of pages11
JournalJournal of Virology
Volume90
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Coronavirus Infections
lethal genes
animal models
Lethal Dose 50
lethal dose 50
infection
Infection
mice
Transgenic Mice
Vaccines
lungs
genetically modified organisms
vaccines
Viruses
Lung
viruses
Middle East respiratory syndrome coronavirus
Middle East Respiratory Syndrome Coronavirus
lethal dose
tissue distribution

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. / Tao, Xinrong; Garron, Tania; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Peng, Bihung; Wakamiya, Maki; Chan, Teh Sheng; Lu, Lu; Du, Lanying; Jiang, Shibo; Couch, Robert B.; Tseng, Chien-Te.

In: Journal of Virology, Vol. 90, No. 1, 2016, p. 57-67.

Research output: Contribution to journalArticle

Tao, X, Garron, T, Agrawal, AS, Algaissi, A, Peng, B, Wakamiya, M, Chan, TS, Lu, L, Du, L, Jiang, S, Couch, RB & Tseng, C-T 2016, 'Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease', Journal of Virology, vol. 90, no. 1, pp. 57-67. https://doi.org/10.1128/JVI.02009-15
Tao, Xinrong ; Garron, Tania ; Agrawal, Anurodh Shankar ; Algaissi, Abdullah ; Peng, Bihung ; Wakamiya, Maki ; Chan, Teh Sheng ; Lu, Lu ; Du, Lanying ; Jiang, Shibo ; Couch, Robert B. ; Tseng, Chien-Te. / Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. In: Journal of Virology. 2016 ; Vol. 90, No. 1. pp. 57-67.
@article{3eeb489386794846bd784b360f6571d4,
title = "Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease",
abstract = "Characterized animal models are needed for studying the pathogenesis of and evaluating medical countermeasures for persisting Middle East respiratory syndrome-coronavirus (MERS-CoV) infections. Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease that globally expresses human CD26 (hCD26)/DPP4. The 50{\%} infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively. Neutralizing antibody developed in the surviving mice from the ID50/LD50 determinations, and all were fully immune to challenge with 100 LD50 of MERS-CoV. The tissue distribution and histopathology in mice challenged with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated. In contrast to the overwhelming infection seen in the mice challenged with 105 LD50 of MERS-CoV, we were able to recover infectious virus from these mice only infrequently, although quantitative reverse transcription-PCR (qRT-PCR) tests indicated early and persistent lung infection and delayed occurrence of brain infection. Persistent inflammatory infiltrates were seen in the lungs and brain stems at day 2 and day 6 after infection, respectively. While focal infiltrates were also noted in the liver, definite pathology was not seen in other tissues. Finally, using a receptor binding domain protein vaccine and a MERS-CoV fusion inhibitor, we demonstrated the value of this model for evaluating vaccines and antivirals against MERS. As outcomes of MERS-CoV infection in patients differ greatly, ranging from asymptomatic to overwhelming disease and death, having available both an infection model and a lethal model makes this transgenic mouse model relevant for advancing MERS research.",
author = "Xinrong Tao and Tania Garron and Agrawal, {Anurodh Shankar} and Abdullah Algaissi and Bihung Peng and Maki Wakamiya and Chan, {Teh Sheng} and Lu Lu and Lanying Du and Shibo Jiang and Couch, {Robert B.} and Chien-Te Tseng",
year = "2016",
doi = "10.1128/JVI.02009-15",
language = "English (US)",
volume = "90",
pages = "57--67",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease

AU - Tao, Xinrong

AU - Garron, Tania

AU - Agrawal, Anurodh Shankar

AU - Algaissi, Abdullah

AU - Peng, Bihung

AU - Wakamiya, Maki

AU - Chan, Teh Sheng

AU - Lu, Lu

AU - Du, Lanying

AU - Jiang, Shibo

AU - Couch, Robert B.

AU - Tseng, Chien-Te

PY - 2016

Y1 - 2016

N2 - Characterized animal models are needed for studying the pathogenesis of and evaluating medical countermeasures for persisting Middle East respiratory syndrome-coronavirus (MERS-CoV) infections. Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease that globally expresses human CD26 (hCD26)/DPP4. The 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively. Neutralizing antibody developed in the surviving mice from the ID50/LD50 determinations, and all were fully immune to challenge with 100 LD50 of MERS-CoV. The tissue distribution and histopathology in mice challenged with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated. In contrast to the overwhelming infection seen in the mice challenged with 105 LD50 of MERS-CoV, we were able to recover infectious virus from these mice only infrequently, although quantitative reverse transcription-PCR (qRT-PCR) tests indicated early and persistent lung infection and delayed occurrence of brain infection. Persistent inflammatory infiltrates were seen in the lungs and brain stems at day 2 and day 6 after infection, respectively. While focal infiltrates were also noted in the liver, definite pathology was not seen in other tissues. Finally, using a receptor binding domain protein vaccine and a MERS-CoV fusion inhibitor, we demonstrated the value of this model for evaluating vaccines and antivirals against MERS. As outcomes of MERS-CoV infection in patients differ greatly, ranging from asymptomatic to overwhelming disease and death, having available both an infection model and a lethal model makes this transgenic mouse model relevant for advancing MERS research.

AB - Characterized animal models are needed for studying the pathogenesis of and evaluating medical countermeasures for persisting Middle East respiratory syndrome-coronavirus (MERS-CoV) infections. Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease that globally expresses human CD26 (hCD26)/DPP4. The 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively. Neutralizing antibody developed in the surviving mice from the ID50/LD50 determinations, and all were fully immune to challenge with 100 LD50 of MERS-CoV. The tissue distribution and histopathology in mice challenged with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated. In contrast to the overwhelming infection seen in the mice challenged with 105 LD50 of MERS-CoV, we were able to recover infectious virus from these mice only infrequently, although quantitative reverse transcription-PCR (qRT-PCR) tests indicated early and persistent lung infection and delayed occurrence of brain infection. Persistent inflammatory infiltrates were seen in the lungs and brain stems at day 2 and day 6 after infection, respectively. While focal infiltrates were also noted in the liver, definite pathology was not seen in other tissues. Finally, using a receptor binding domain protein vaccine and a MERS-CoV fusion inhibitor, we demonstrated the value of this model for evaluating vaccines and antivirals against MERS. As outcomes of MERS-CoV infection in patients differ greatly, ranging from asymptomatic to overwhelming disease and death, having available both an infection model and a lethal model makes this transgenic mouse model relevant for advancing MERS research.

UR - http://www.scopus.com/inward/record.url?scp=84953931577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953931577&partnerID=8YFLogxK

U2 - 10.1128/JVI.02009-15

DO - 10.1128/JVI.02009-15

M3 - Article

VL - 90

SP - 57

EP - 67

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 1

ER -